

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Elafibranor for treating primary biliary cholangitis [ID6331]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Ipsen Ltd (Elafibranor) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • Black Health Agency • Bladder and Bowel Community • British Liver Trust • Guts UK • Liver4Life • PBC Foundation • PSC Support • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • British Association for the Study of the Liver • British Geriatrics Society • British Hepatology Pharmacist Group • British Liver Nurses' Association • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • ADVANZ Pharma (Ursodeoxycholic acid, Obeticholic acid) • Dr. Falk Pharma UK Ltd (Ursodeoxycholic acid) • Galen Limited (Ursodeoxycholic acid) • Glenmark Pharmaceuticals Europe Ltd (Ursodeoxycholic acid) • Norgine Limited (Ursodeoxycholic acid) • Strides Pharma UK Ltd (Ursodeoxycholic acid) • Wockhardt UK Ltd (Ursodeoxycholic acid)

Final stakeholder list for the evaluation of Elafibranor for treating primary biliary cholangitis [ID6331]
Issue date: February 2024

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • <u>Relevant research groups</u> • Cochrane Hepato-Biliary Group • Cochrane UK • Foundation for Liver Research • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Final stakeholder list for the evaluation of Elafibranor for treating primary biliary cholangitis [ID6331]
Issue date: February 2024

